Atara Biotherapeutics
ATRA
ATRA
139 hedge funds and large institutions have $316M invested in Atara Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 53 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
16% less capital invested
Capital invested by funds: $376M → $316M (-$59.9M)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
139
Holding in Top 10
1
Calls
$5.13M
Puts
$26K
Top Buyers
| 1 | +$4.87M | |
| 2 | +$4.48M | |
| 3 | +$2.66M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
+$2.47M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.99M |
Top Sellers
| 1 | -$5.13M | |
| 2 | -$4.91M | |
| 3 | -$2.73M | |
| 4 |
JPMorgan Chase & Co
New York
|
-$2.57M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.62M |